Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heinrich, M. C.
Right arrow Articles by Corless, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heinrich, M. C.
Right arrow Articles by Corless, C. L.
Journal of Clinical Oncology, Vol 20, Issue 6 (March), 2002: 1692-1703
© 2002 American Society for Clinical Oncology

REVIEW ARTICLE

Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies

By Michael C. Heinrich, Charles D. Blanke, Brian J. Druker, Christopher L. Corless

From the Department of Medicine, Division of Hematology/Oncology and Department of Pathology and Laboratory Medicine, Oregon Health and Science University; and Portland Veterans Affairs Medical Center, Portland, OR.

Address reprint requests to Michael Heinrich, MD, R&D-19 3710 SW US Veterans Hospital Rd, Portland, OR 97207; email: heinrich@ ohsu.edu.

PURPOSE: Activation of the KIT tyrosine kinase by somatic mutation has been documented in a number of human malignancies, including gastrointestinal stromal tumor (GIST), seminoma, acute myelogenous leukemia (AML), and mastocytosis. In addition, paracrine or autocrine activation of this kinase has been postulated in numerous other malignancies, including small-cell lung cancer and ovarian cancer. In this review, we discuss the rationale for and development of KIT tyrosine kinase inhibitors for the treatment of human malignancies.

MATERIALS AND METHODS: Studies were identified through a MEDLINE search, review of bibliographies of relevant articles, and review of abstracts from national meetings.

RESULTS: Four tyrosine kinase inhibitors that have activity against KIT are currently being used in clinical trials, and one, STI571, has recently been approved by the United States Food and Drug Administration for treating patients with chronic myelogenous leukemia. The role of KIT inhibitors in treating KIT-positive malignancies is reviewed.

CONCLUSION: Targeted therapy to inhibit the kinase activity of KIT is a rational approach to the treatment of KIT-positive malignancies. Two key factors are the potency of a given inhibitor and the relative contribution of KIT activation to the growth of the tumor. Given our current understanding of KIT activity in human malignancy, the best candidate diseases for treatment with KIT inhibitors are GIST, mastocytosis, seminoma and possibly some cases of AML. Additionally, KIT inhibitors may play an adjunctive role in diseases such as small-cell lung cancer, in which KIT activation is secondary to ligand binding rather than an acquired mutation.




This article has been cited by other articles:


Home page
 haematolHome page
J. C. Montero, R. Lopez-Perez, J. F. San Miguel, and A. Pandiella
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity
Haematologica, June 1, 2008; 93(6): 851 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, et al.
Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations
Ann. Onc., May 29, 2008; (2008) mdn352v1.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. M. Croce
Oncogenes and Cancer
N. Engl. J. Med., January 31, 2008; 358(5): 502 - 511.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C. Jones, M. Rodriguez-Pinilla, M. Lambros, D. Bax, B. Messahel, G. M Vujanic, J. S Reis-Filho, and K. Pritchard-Jones
c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours
J. Clin. Pathol., November 1, 2007; 60(11): 1226 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
G. Portale, G. Zaninotto, M. Costantini, M. Rugge, G. M. Pennelli, S. Rampado, P. Bocus, and E. Ancona
Esophageal GIST: Case Report of Surgical Enucleation and Update on Current Diagnostic and Therapeutic Options
International Journal of Surgical Pathology, October 1, 2007; 15(4): 393 - 396.
[Abstract] [PDF]

Home page
 Endocr Relat CancerHome page
M. Brama, S. Basciani, S. Cherubini, S. Mariani, S. Migliaccio, M. Arizzi, G. Rosano, G. Spera, and L. Gnessi
Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment
Endocr. Relat. Cancer, March 1, 2007; 14(1): 61 - 72.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Q.M. Chow and S. G. Eckhardt
Sunitinib: From Rational Design to Clinical Efficacy
J. Clin. Oncol., March 1, 2007; 25(7): 884 - 896.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Katiyar, X. Jiao, E. Wagner, M. P. Lisanti, and R. G. Pestell
Somatic Excision Demonstrates that c-Jun Induces Cellular Migration and Invasion through Induction of Stem Cell Factor
Mol. Cell. Biol., February 15, 2007; 27(4): 1356 - 1369.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
D. R Stewart, C. L Corless, B. P Rubin, M. C Heinrich, L. M Messiaen, L. J Kessler, P. J Zhang, and D. G Brooks
Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1
J. Med. Genet., January 1, 2007; 44(1): e61 - e61.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
D. A. Thomas
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges
Hematology, January 1, 2007; 2007(1): 435 - 443.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Pan, A. Quintas-Cardama, H. M. Kantarjian, C. Akin, T. Manshouri, P. Lamb, J. E. Cortes, A. Tefferi, F. J. Giles, and S. Verstovsek
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
Blood, January 1, 2007; 109(1): 315 - 322.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
H. M. Kantarjian, M. Talpaz, F. Giles, S. O'Brien, and J. Cortes
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Ann Intern Med, December 19, 2006; 145(12): 913 - 923.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Hu, S. Swerdlow, T. M. Duffy, R. Weinmann, F. Y. Lee, and S. Li
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
PNAS, November 7, 2006; 103(45): 16870 - 16875.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
C. L. Corless, P. Harrell, M. Lacouture, T. Bainbridge, C. Le, K. Gatter, C. White Jr, S. Granter, and M. C. Heinrich
Allele-Specific Polymerase Chain Reaction for the Imatinib-Resistant KIT D816V and D816F Mutations in Mastocytosis and Acute Myelogenous Leukemia
J. Mol. Diagn., November 1, 2006; 8(5): 604 - 612.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Polverino, A. Coxon, C. Starnes, Z. Diaz, T. DeMelfi, L. Wang, J. Bready, J. Estrada, R. Cattley, S. Kaufman, et al.
AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts.
Cancer Res., September 1, 2006; 66(17): 8715 - 8721.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Ishikubo, K. Akagi, M. Kurosumi, K. Yamaguchi, T. Fujimoto, H. Sakamoto, Y. Tanaka, and A. Ochiai
Immunohistochemical and Mutational Analysis of c-kit in Gastrointestinal Neuroendocrine Cell Carcinoma
Jpn. J. Clin. Oncol., August 1, 2006; 36(8): 494 - 498.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Gabillot-Carre, Y. Lepelletier, M. Humbert, P. de Sepuvelda, N. B. Hamouda, J. P. Zappulla, R. Liblau, A. Ribadeau-Dumas, F. Machavoine, S. Letard, et al.
Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells
Blood, August 1, 2006; 108(3): 1065 - 1072.
[Abstract] [Full Text] [PDF]

Home page
 IEICE Trans FundamentalsHome page
M. A. RAHMAN, S. SASAKI, and H. KIKUCHI
Error Analysis for Ultra-Wideband DS- and Hybrid DS/TH-CDMA with Arbitrary Chip-Duty
IEICE Trans A: Fundamentals, June 1, 2006; E89-A(6): 1668 - 1679.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Litz and G. W. Krystal
Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1{alpha} activity and vascular endothelial growth factor expression in small cell lung cancer cells.
Mol. Cancer Ther., June 1, 2006; 5(6): 1415 - 1422.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
O. Potapova, A. D. Laird, M. A. Nannini, A. Barone, G. Li, K. G. Moss, J. M. Cherrington, and D. B. Mendel
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
Mol. Cancer Ther., May 1, 2006; 5(5): 1280 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Z. Zhang and K. E. Meier
New Assignments for Multitasking Signal Transduction Inhibitors
Mol. Pharmacol., May 1, 2006; 69(5): 1510 - 1512.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Garton, A. P.A. Crew, M. Franklin, A. R. Cooke, G. M. Wynne, L. Castaldo, J. Kahler, S. L. Winski, A. Franks, E. N. Brown, et al.
OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models
Cancer Res., January 15, 2006; 66(2): 1015 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Cammenga, S. Horn, U. Bergholz, G. Sommer, P. Besmer, W. Fiedler, and C. Stocking
Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate
Blood, December 1, 2005; 106(12): 3958 - 3961.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
A Leithner, M Gapp, R Radl, A Pascher, P Krippl, K Leithner, R Windhager, and A Beham
Immunohistochemical analysis of desmoid tumours
J. Clin. Pathol., November 1, 2005; 58(11): 1152 - 1156.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. K. Dy, A. A. Miller, S. J. Mandrekar, M.-C. Aubry, R. M. Langdon Jr., R. F. Morton, S. E. Schild, J. R. Jett, and A. A. Adjei
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study
Ann. Onc., November 1, 2005; 16(11): 1811 - 1816.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
S. Appel, S. Balabanov, T. H. Brummendorf, and P. Brossart
Effects of Imatinib on Normal Hematopoiesis and Immune Activation
Stem Cells, September 1, 2005; 23(8): 1082 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. P. Rubin, C. R. Antonescu, J. P. Scott-Browne, M. L. Comstock, Y. Gu, M. R. Tanas, C. B. Ware, and J. Woodell
A Knock-In Mouse Model of Gastrointestinal Stromal Tumor Harboring Kit K641E
Cancer Res., August 1, 2005; 65(15): 6631 - 6639.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. Nakagawa, Y. Matsuno, H. Kunitoh, A. Maeshima, H. Asamura, and R. Tsuchiya
Immunohistochemical KIT (CD117) Expression in Thymic Epithelial Tumors
Chest, July 1, 2005; 128(1): 140 - 144.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. S. Corbin, S. Demehri, I. J. Griswold, Y. Wang, C. A. Metcalf III, R. Sundaramoorthi, W. C. Shakespeare, J. Snodgrass, S. Wardwell, D. Dalgarno, et al.
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit
Blood, July 1, 2005; 106(1): 227 - 234.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
S. BALABANOV, S. APPEL, L. KANZ, P. BROSSART, and T. H. BRUMMENDORF
Effect of Tyrosine Kinase Inhibition Using Imatinib on Normal Lymphohematopoietic Cells
Ann. N.Y. Acad. Sci., June 1, 2005; 1044(1): 168 - 177.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Tarn, E. Merkel, A. A. Canutescu, W. Shen, Y. Skorobogatko, M. J. Heslin, B. Eisenberg, R. Birbe, A. Patchefsky, R. Dunbrack, et al.
Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling
Clin. Cancer Res., May 15, 2005; 11(10): 3668 - 3677.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Okuno, W. J. Maples, M. R. Mahoney, T. Fitch, J. Stewart, P. M. Fracasso, M. Kraut, D. S. Ettinger, F. Dawkins, and C. Erlichman
Evaluation of Epothilone B Analog in Advanced Soft Tissue Sarcoma: A Phase II Study of the Phase II Consortium
J. Clin. Oncol., May 1, 2005; 23(13): 3069 - 3073.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
J. M. Cherrington
Taking Biological Targeted Agents into Clinical Trial
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 23 - 29.
[Full Text] [PDF]

Home page
 aacredbookHome page
J. B. McMahon, K. R. Gustafson, and C. J. Henrich
Molecular-Targeted Drug Screening at the NCI Center for Cancer Research
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 125 - 129.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Basciani, M. Brama, S. Mariani, G. De Luca, M. Arizzi, L. Vesci, C. Pisano, S. Dolci, G. Spera, and L. Gnessi
Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for In vitro and In vivo Activity
Cancer Res., March 1, 2005; 65(5): 1897 - 1903.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Appel, A. Rupf, M. M. Weck, O. Schoor, T. H. Brummendorf, T. Weinschenk, F. Grunebach, and P. Brossart
Effects of Imatinib on Monocyte-Derived Dendritic Cells Are Mediated by Inhibition of Nuclear Factor-{kappa}B and Akt Signaling Pathways
Clin. Cancer Res., March 1, 2005; 11(5): 1928 - 1940.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Jelacic and D. Linnekin
PKC{delta} plays opposite roles in growth mediated by wild-type Kit and an oncogenic Kit mutant
Blood, March 1, 2005; 105(5): 1923 - 1929.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Wang, F. Cheng, A. Cuenca, P. Horna, Z. Zheng, K. Bhalla, and E. M. Sotomayor
Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance
Blood, February 1, 2005; 105(3): 1135 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Sihto, M. Sarlomo-Rikala, O. Tynninen, M. Tanner, L. C. Andersson, K. Franssila, N. N. Nupponen, and H. Joensuu
KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors
J. Clin. Oncol., January 1, 2005; 23(1): 49 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
J. Lennartsson, T. Jelacic, D. Linnekin, and R. Shivakrupa
Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit
Stem Cells, January 1, 2005; 23(1): 16 - 43.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Blood, January 1, 2005; 105(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. S. Corbin, I. J. Griswold, P. La Rosee, K. W. H. Yee, M. C. Heinrich, C. L. Reimer, B. J. Druker, and M. W. N. Deininger
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970
Blood, December 1, 2004; 104(12): 3754 - 3757.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. B. Dietz, L. Souan, G. J. Knutson, P. A. Bulur, M. R. Litzow, and S. Vuk-Pavlovic
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
Blood, August 15, 2004; 104(4): 1094 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
C. All-Ericsson, L. Girnita, A. Muller-Brunotte, B. Brodin, S. Seregard, A. Ostman, and O. Larsson
c-Kit-Dependent Growth of Uveal Melanoma Cells: A Potential Therapeutic Target?
Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2075 - 2082.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Blay, A. Astudillo, J. M. Buesa, E. Campo, M. Abad, J. Garcia-Garcia, R. Miquel, V. Marco, M. Sierra, R. Losa, et al.
Protein Kinase C {theta} Is Highly Expressed in Gastrointestinal Stromal Tumors But Not in Other Mesenchymal Neoplasias
Clin. Cancer Res., June 15, 2004; 10(12): 4089 - 4095.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Spatz, B. B.-d. Paillerets, and E. Raymond
Soft Tissue Sarcomas: CASE 3. Gastrointestinal Stromal Tumor and Carney's Triad
J. Clin. Oncol., May 15, 2004; 22(10): 2029 - 2031.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. R. Antonescu, A. Viale, L. Sarran, S. J. Tschernyavsky, M. Gonen, N. H. Segal, R. G. Maki, N. D. Socci, R. P. DeMatteo, and P. Besmer
Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site
Clin. Cancer Res., May 15, 2004; 10(10): 3282 - 3290.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
B. L. Eisenberg and I. Judson
Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy
Ann. Surg. Oncol., May 1, 2004; 11(5): 465 - 475.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
D Miliaras, F Karasavvidou, A Papanikolaou, and D Sioutopoulou
KIT expression in fetal, normal adult, and neoplastic renal tissues
J. Clin. Pathol., May 1, 2004; 57(5): 463 - 466.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. R. Raspollini, G. Amunni, A. Villanucci, G. Baroni, A. Taddei, and G. L. Taddei
c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study
Ann. Onc., April 1, 2004; 15(4): 594 - 597.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. P. Paronetto, D. Farini, I. Sammarco, G. Maturo, G. Vespasiani, R. Geremia, P. Rossi, and C. Sette
Expression of a Truncated Form of the c-Kit Tyrosine Kinase Receptor and Activation of Src Kinase in Human Prostatic Cancer
Am. J. Pathol., April 1, 2004; 164(4): 1243 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Fumo, C. Akin, D. D. Metcalfe, and L. Neckers
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells
Blood, February 1, 2004; 103(3): 1078 - 1084.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Gonzalez, E. J. Andreu, A. Panizo, S. Inoges, A. Fontalba, J. L. Fernandez-Luna, M. Gaboli, L. Sierrasesumaga, S. Martin-Algarra, J. Pardo, et al.
Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis
Clin. Cancer Res., January 15, 2004; 10(2): 751 - 761.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Appel, A. M. Boehmler, F. Grunebach, M. R. Muller, A. Rupf, M. M. Weck, U. Hartmann, V. L. Reichardt, L. Kanz, T. H. Brummendorf, et al.
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells
Blood, January 15, 2004; 103(2): 538 - 544.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. Casali, A. Stefani, G. Rossi, M. Migaldi, S. Bettelli, A. Parise, and U. Morandi
The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung
Ann. Thorac. Surg., January 1, 2004; 77(1): 247 - 252.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Kemmer, C. L. Corless, J. A. Fletcher, L. McGreevey, A. Haley, D. Griffith, O. W. Cummings, C. Wait, A. Town, and M. C. Heinrich
KIT Mut